Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ: SNGX )

2.070 UNCHANGED
Streaming Delayed Price Updated: 3:52 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 75
Open 2.070
Bid (Size) 1.950 (15)
Ask (Size) 2.040 (1)
Prev. Close 2.070
Today's Range 2.070 - 2.070
52wk Range 1.680 - 14.83
Shares Outstanding 3,155,603
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
Via Investor Brand Network
Topics Death
Exposures COVID-19 Death
Study Finds Link Between Childhood Maltreatment and Elevated Risk of Psoriasis, Rheumatoid Arthritis
Via Investor Brand Network

Performance

YTD
-29.59%
-29.59%
1 Month
-9.61%
-9.61%
3 Month
-15.85%
-15.85%
6 Month
-42.18%
-42.18%
1 Year
-67.66%
-67.66%

More News

Read More
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Study Shows the Gut is Key in Protecting the Brain After Stroke
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
Via Investor Brand Network
BioMedNewsBreaks — Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results
Via Investor Brand Network
Exposures COVID-19
Study Shows Bioengineered Materials Can Treat Oral Mucositis
Via Investor Brand Network
BioMedNewsBreaks — Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Via Investor Brand Network
Exposures COVID-19
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Via Investor Brand Network
Soligenix Aims To Push The Boundaries In Treating Rare Diseases
Via NewMediaWire
Soligenix Aims To Push The Boundaries In Treating Rare Diseases
Via TheNewswire.com
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
Via NewMediaWire
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
Via TheNewswire.com
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
Via NewMediaWire
Exposures COVID-19
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
Via TheNewswire.com
Exposures COVID-19
Soligenix Targets Psoriasis With New Therapy
Via News Direct
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
Via Benzinga
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
Via News Direct
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer
Via Benzinga
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
Via News Direct
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.